BCL2 and neoplasm: In the univariate analysis, a normal serum LDH (p = 0.008), an ECOG performance score of 2–3 (p = 0.002), lower risk IELSG group (p < 0.001), no CSF seeding (p = 0.013), homogeneous enhancement on MRI (p = 0.034), gross total tumor resection (p = 0.004), negative immunoreactivity of BCL2 (p = 0.011), negative immunoreactivity of p53 (p = 0.014), negative immunoreactivity of MUM1 (p = 0.002), and negative immunoreactivity of c-Myc (p = 0.008) were associated with long PFS (Table 4).